Clinical trials: Stroke Treatment
- Condition Stroke Treatment
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Thrombosis, Acute Coronary Syndrome
Safety, Pharmacokinetic and -Dynamic Study of PR-15, an Inhibitor of Platelet Adhesion
Primary objective: To evaluate safety and tolerability, adverse events (AEs), vital signs, ECG, bleeding time, evaluation of antibody titer and safety laboratory tests Secondary objectives: To evaluate the pharmacokinetics and…
- Conditions
- Thrombosis, Acute Coronary Syndrome, Myocardial Infarction, Stroke
- Trial name
- PR-15/01 (NCT01042964)
- Testing
- revacept (PR-15)
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AdvanceCor GmbH
Ischemic Stroke
Mexidol® Safety and Efficacy in Treatment of Hyperacute and Acute Ischemic Stroke
The primary objective of this study is to further define the mechanisms of action of Mexidol® (solution for intravenous and intramuscular injection, 50 mg/ml) and Mexidol® FORTE 250 (film-coated tablets, 250 mg) in the hyperacute…
- Trial name
- NCT07575984
- Testing
- Mexidol, Glycine
- Where
- 9 sites in Russia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Pharmasoft
Orthopedic Disorder, Neurologic Disorder
Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions
To determine the safety and efficacy of Amniotic and Umbilical Cord Tissue for the treatment of the following condition categories: Orthopedic, Neurologic, Urologic, Autoimmune, Renal, Cardiac and Pulmonary Conditions.
- Conditions
- Orthopedic Disorder, Neurologic Disorder, Urologic Diseases, Erectile Dysfunction
- Trial name
- NCT03899298
- Testing
- Amniotic and Umbilical Cord Tissue Procedure
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- R3 Stem Cell
Acute Ischemic Stroke
DS1040b/Aspirin Drug/Drug Interaction Study
This is a phase 1, open label, single dose study, after 5 days of aspirin treatment, in healthy male and female subjects. It is hypothesized that co-administering DS-1040b with aspirin at steady state will be safe and well…
- Trial name
- NCT02071004
- Testing
- DS-1040b, Aspirin
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo
Stroke
An Open Label, Phase 1b, Ascending Dose Study of DM199
This is a Phase 1B study to assess the safety, tolerability and pharmacokinetics of DM199 in healthy volunteers. The study will be consist of two parts: Part A will focus on intravenous dosing and Part B will directly compare…
- Trial name
- NCT02868996
- Testing
- Recombinant human tissue kallikrein
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- DiaMedica Therapeutics Inc
Ischemic Stroke, Acute, Stroke
NeuroGlove fMRI Study
This is a prospective, single center, interventional clinical study containing two cohorts the treatment cohort and control cohort. A total of 13 subjects will be enrolled.
- Trial name
- NCT05961293
- Testing
- NeuroGlove
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- NeuroGlove LLC
First-In-Human Study to Evaluate Safety of a New Drug Intended for Treatment of Acute Ischemic Stroke
A Phase 1 Study to Evaluate Safety and Tolerability of NoNO-42 in Healthy Adults
The purpose of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics of a single ascending intravenous dose of NoNO-42 administered to healthy adults.
- Trial name
- NCT05636306
- Testing
- NoNO-42
- Where
- Canada
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- NoNO Inc.
Cardiovascular Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects
Part A of this study is a Phase 1, First-in-human (FiH), randomized, single-blind, placebo controlled study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD3366 following single…
- Trial name
- NCT04588727
- Testing
- AZD3366, Ticagrelor, acetylsalicylic acid (ASA)
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Cerebrovascular Accident
Anti-MAG First Administration to Human
GSK249320 is a monoclonal antibody directed against myelin associated glycoprotein (MAG), a protein that inhibits axonal regeneration.
- Trial name
- NCT00622609
- Testing
- GSK249320A
- Where
- 2 sites in United States, Australia
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Ischemic Stroke
Safety and Pharmacokinetics of Multiple Dose of YC-6 in Healthy Subjects
The study is designed to determine the safety, tolerability, and pharmacokinetics in healthy subjects with multiple intravenous administration of the neuroprotectant YC-6 compared to placebo.
- Trial name
- NCT03358901
- Testing
- YC-6, Vehicle
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Guangzhou Cellprotek Pharmaceutical Co., Ltd.
Acute Ischemic Stroke
Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor
Single-chain urokinase-type plasminogen activator (pro-urokinase) is a highly effective thrombolytic drug. At pharmacologic concentrations however, pro-urokinase is converted to urokinase - a non specific thrombolytic, limiting…
- Trial name
- NCT01694381
- Testing
- M5, C1-inhibitor
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- TSI, LLC
Acute Ischemic Stroke
Prospective Registry for Assessment of Acute Ischemic Stroke Patients Treated With Neurothrombectomy Devices in India
PRAAN is a post-market registry designed to collect real-world data associated with the use of Medtronic market release neurothrombectomy devices in acute ischemic stroke (AIS) patients from India.
- Trial name
- PRAAN (NCT05005962)
- Testing
- Neurothrombectomy
- Where
- 14 sites in India
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Medtronic Neurovascular Clinical Affairs
Ischemic Stroke
Safety, Tolerability and Pharmacokinetic Characteristics Evaluation on DA414
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and Food Effects of DA414 Granules in Chinese healthy subjects with single and multiple doses.
- Trial name
- DA414 (NCT06525168)
- Testing
- DA414 Granules
- Where
- China
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Chendu DIAO Nine Hong Pharmaceutical Factory
Prevention of Thromboembolic Events, Atrial Fibrillation
A Study to Learn How the Study Treatment Asundexian Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body in Participants With Mild or Moderate Reduction of Liver Function Compared to Participants With Normal Liver Function
Researchers are looking for a better way to prevent the formation of blood clots in people who have or have had: an irregular and often rapid heartbeat a blocked blood flow to the heart a blocked or reduced blood flow to a part…
- Conditions
- Prevention of Thromboembolic Events, Atrial Fibrillation, Acute Myocardial Infarction, Non-cardioembolic Ischemic Stroke
- Trial name
- NCT05419635
- Testing
- Asundexian (BAY2433334)
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Bayer
Stroke
Effect of Personalized Robotic Therapy
The primary goal of this project is to test the safeness and clinical effectiveness of a novel exoskeleton for the upper limb (Arm Light Exoskeleton Rehab Station, ALEx RS) developed at Wearable Robotics srl, for the force…
- Trial name
- NCT02770300
- Testing
- Arm Light Exoskeleton Rehab Station (ALEx RS), Arm Light Exoskeleton Rehab Station (ALEx RS) - automatically personalized
- Where
- Switzerland
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Wearable Robotics srl.